Skip to content
Storytelling Co – Lifestyle
Author:
Annovis Bio Inc.
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
August 14, 2026
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
July 7, 2026
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
July 1, 2026
Annovis Bio Regains NYSE Listing Compliance
May 26, 2026
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
May 20, 2026
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
May 19, 2026
Annovis Publishes Phase 2/3 Alzheimer’s Trial Results in Nature Portfolio
April 29, 2026
←
Previous Page
1
2